Circulating Mir-26A and Mir-21 As Biomarkers for Glioblastoma Multiform

Circulating Mir-26A and Mir-21 As Biomarkers for Glioblastoma Multiform Publisher Pubmed

Parvizhamidi M¹ ; Haddad G² ; Ostadrahimi S¹ ; Ostadrahimi N³ ; Sadeghi S¹ ; Fayaz S¹ ; Fardesfahani P¹

Show Affiliations

1. Department of Biochemistry, Pasteur Institute of Iran, Tehran, Iran
2. Molecular Genetics and Microbiology, University of Toronto, Toronto, ON, Canada
3. Neurosurgery Ward, Imam Khomeini hospital complex, Tehran, Iran

Source: Biotechnology and Applied Biochemistry Published:2019

Abstract

Glioblastoma multiform is the most common and lethal primary central nervous system tumor. Circulating microRNAs (miRNAs), present in cell-free bodily fluids, have been gaining importance as cancer biomarkers. The primary aim of this study was to assess whether circulating miRNA-128, -21, and -26a in glioblastoma patients can be used as diagnostic biomarkers. Venous blood samples were collected from 11 noncancerous volunteers and 15 glioblastoma patients pre- and post operation. Also, tissue tumor samples were obtained intra-operationally to assay consistency of miRNA levels in serum and tissue samples. Serum and tissue levels of miRNAs were determined by quantitative reverse transcription PCR. miR-21 and miR-26a were both significantly upregulated in pre- and postoperation serum samples of glioblastoma patients compared with the serum samples of noncancerous controls. We found that all three miR-128, -21, and -26a expression levels were reduced in postoperative serum samples compared with pre-operative serum samples, though this decrease was only significant for miR-26a. The serum miR-26a and miR-21 upregulation in glioblastoma patients compared to noncancerous controls and their downregulation in postoperative serum from glioblastoma patients suggest that these miRNAs could be used as serum-derived miRNA biomarkers for glioblastoma. © 2018 International Union of Biochemistry and Molecular Biology, Inc.

Style	Citing Format
MLA	Parvizhamidi M, et al.. "Circulating Mir-26A and Mir-21 As Biomarkers for Glioblastoma Multiform." Biotechnology and Applied Biochemistry, vol. 66, no. 2, 2019, pp. 261-265.
APA	Parvizhamidi M, Haddad G, Ostadrahimi S, Ostadrahimi N, Sadeghi S, Fayaz S, Fardesfahani P (2019). Circulating Mir-26A and Mir-21 As Biomarkers for Glioblastoma Multiform. Biotechnology and Applied Biochemistry, 66(2), 261-265.
Chicago	Parvizhamidi M, Haddad G, Ostadrahimi S, Ostadrahimi N, Sadeghi S, Fayaz S, Fardesfahani P. "Circulating Mir-26A and Mir-21 As Biomarkers for Glioblastoma Multiform." Biotechnology and Applied Biochemistry 66, no. 2 (2019): 261-265.
Harvard	Parvizhamidi M et al. (2019) 'Circulating Mir-26A and Mir-21 As Biomarkers for Glioblastoma Multiform', Biotechnology and Applied Biochemistry, 66(2), pp. 261-265.
Vancouver	Parvizhamidi M, Haddad G, Ostadrahimi S, Ostadrahimi N, Sadeghi S, Fayaz S, et al.. Circulating Mir-26A and Mir-21 As Biomarkers for Glioblastoma Multiform. Biotechnology and Applied Biochemistry. 2019;66(2):261-265.
BibTex	@article{ author = {Parvizhamidi M and Haddad G and Ostadrahimi S and Ostadrahimi N and Sadeghi S and Fayaz S and Fardesfahani P}, title = {Circulating Mir-26A and Mir-21 As Biomarkers for Glioblastoma Multiform}, journal = {Biotechnology and Applied Biochemistry}, volume = {66}, number = {2}, pages = {261-265}, year = {2019} }
RIS	TY - JOUR AU - Parvizhamidi M AU - Haddad G AU - Ostadrahimi S AU - Ostadrahimi N AU - Sadeghi S AU - Fayaz S AU - Fardesfahani P TI - Circulating Mir-26A and Mir-21 As Biomarkers for Glioblastoma Multiform JO - Biotechnology and Applied Biochemistry VL - 66 IS - 2 SP - 261 EP - 265 PY - 2019 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract